Home › Acute Myeloid Leukemia › California
Acute Myeloid Leukemia clinical trials in California
79 studies for Acute Myeloid Leukemia are looking for participants at sites in California.
Cities in California
- Baldwin Park41 studies
- Los Angeles25 studies
- Mountain View19 studies
- Orange12 studies
- Sacramento12 studies
- San Francisco12 studies
- San Diego7 studies
- Oakland7 studies
- Fresno5 studies
- Roseville5 studies
- Santa Clara4 studies
- San Bernardino4 studies
- San Jose3 studies
- Santa Rosa3 studies
- Concord3 studies
- Long Beach3 studies
- Irvine3 studies
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
- City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center), Duarte
RecruitingPhase 1
Ages 65 and older · All sexes · Updated Nov 13, 2026 · NCT06552416Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- University of California Davis Comprehensive Cancer Center, Sacramento
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07304011Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- and 17 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of California, Fresno, Clovis
- University of California, San Diego, La Jolla
- Cedars-Sinai Medical Center, Los Angeles
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007312The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
RecruitingPhase 1/2Healthy volunteers welcome
Ages 12 to 120 · All sexes · Updated Nov 10, 2026 · NCT05436418Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Cedars-Sinai Medical Center, Los Angeles
- Kaiser Permanente-Oakland, Oakland
- Kaiser Permanente-Roseville, Roseville
- and 3 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT06996119CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT05672147HPC Offered for PRESERVE Expansion
- City of Hope, Duarte
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Los Angeles CA-UCLA, Los Angeles
- US-San Francisco CA-UCSF, San Francisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07223814A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
- City of Hope Center Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07751991Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- and 22 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- City of Hope, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- and 19 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- City of Hope Comprehensive Cancer Center - Duarte, Duarte
- University of California Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 30, 2026 · NCT05429632225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 30, 2026 · NCT06287944Study of REM-422 in Patients With AML or Higher Risk MDS
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06297941CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- City of Hope, Duarte
- UCLA, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Cedars-Sinai Medical Center, Los Angeles
- Kaiser Permanente-Oakland, Oakland
- Kaiser Permanente-Roseville, Roseville
- and 2 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- UCSF Medical Center-Parnassus, San Francisco
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06672146CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06059391A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- City of Hope Comprehensive Cancer Center, Duarte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06969430A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- UCSF Medical Center-Mission Bay, San Francisco
RecruitingPhase 1
Up to age 21 · All sexes · Updated Oct 23, 2026 · NCT07012044A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT07020533Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Rady Children's Hospital, San Diego
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Oct 22, 2026 · NCT06177067A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- City of Hope National Medical Center /ID# 279568, Duarte
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07581002CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- University of California, Davis Comprehensive Cancer Center, Sacramento
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Oct 21, 2026 · NCT06834282Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Duarte
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 21, 2026 · NCT07211958Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06533761Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06543381A Study of Revumenib and Mezigdomide in People With Leukemia
- City of Hope Cancer Center (Data collection only), Duarte
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 20, 2026 · NCT07356154Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Oct 19, 2026 · NCT06575296Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- City of Hope National Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT06846606Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 2 to 22 · All sexes · Updated Oct 14, 2026 · NCT06128070Niclosamide in Pediatric Patients With Relapsed and Refractory AML
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 2 to 30 · All sexes · Updated Oct 14, 2026 · NCT05188170Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07582172A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04256317Individualized AML Treatment
- City of Hope Medical Center, Duarte
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT07613385A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Lucile Packard Children's Hospital /ID# 276015, Palo Alto
RecruitingPhase 1
6 Months – 17 Years · All sexes · Updated Oct 5, 2026 · NCT07306832A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06763341From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.